Our in vitro biology team has in-depth knowledge of different therapeutic areas and target classes. De novo assay development without any literature precedence for novel target classes or therapeutic indications along with assay customization has added significant value to our Integrated Drug Discovery (IDD) projects and driven compound progression and clinical candidate nomination successfully.
Our offerings include screening and profiling services/platforms under different therapeutic areas and target classes.
In vitro Assay Capabilities
A platform for screening of NCEs and NBEs against major therapeutic target classes: GPCRs, ion channels, proteases, other hydrolytic enzymes, and membrane receptors are a few examples of our experience in target classes.
APSL focuses and caters to a wide range of therapeutic areas like asthma and COPD, metabolic disorders (diabetes, NASH & obesity), inflammation, oncology, immunology, stem cell biology, osteoporosis, angiogenesis, CNS, and pain. We also have experience in epigenetics and Protein-Protein Interaction (PPI) targets. At APSL, we are continuously adding the experience of advanced and emerging drug classes. Examples include PROTAC, Oligonucleotide, ADC, and mRNA. We offer a complete set of bioassays for PROTAC discovery.
In vitro Assay Development
- Phenotypic Assays: Phenotypic assays aim to identify the molecules which can alter a cell's phenotype. Here, we look at the effect of a substance on the entire biological system as opposed to an isolated component of it. Phenotypic Assays are the most refined and delicate of all assays and can be performed in cells, such as stem-cell-derived human cells, isolated tissues, or entire organisms.
- Mechanistic Assays: We have the core expertise for the level of mechanistic understanding required for drug discovery. Mechanistic assays are an important part of in vitro service portfolio, as they provide further information about the cell mechanism displayed by the study compound. All assays are with fluorescence or luminescence endpoints.
- Cell-based Assays: To understand the correlation of networks in a complex biological system, we can design custom cell-based assays that cater to every stage of drug development. As a leading CDMO company and Contract research organization, we have at our disposal a wide range of cell types which in combination with innovative technologies result in assays with improved translational success.
- Readout Platforms: We offer diverse readout platforms such as Luminescence, Fluorescence (FRET, TR-FRET), Fluorescence Polarization (FP), AlphaLISA, AlphaScreen, Absorbance, and UV to NIR.
In vitro Assay Capability Range
- Functional Assay
- Cell Viability
- Apoptosis
- Invasion
- Migration
- Cell Senescence
- Cell Cycle Analysis
- Necroptosis Assay
- Pyroptosis Assay
- Specialized Assays
- Target engagement assays via Nano-BRET/ CESTA
- 3D cells co-culture
- Spheroid culture
- Organoid culture
- Stem cell-derived functional cells – Hepatocytes, Cardiac, etc
- Immunological Assays
- Dendritic cell
- T-cell cytotoxicity
- Treg – Immune suppression
- Immune cell profiling
- Mixed lymphocyte
- Biomarker Assay
- Cytokine modulation
- Target gene expression
- Phosphorylation of signaling intermediates
- Cytokine-induced transcription factor phosphorylation
Why Aurigene Pharmaceutical Services?
Complex and specialized assay development
High throughput expression system
Functional, Mechanism of Action (MoA) and target engagement studies
Expertise to support Integrated Drug Discovery programs
Deep therapeutic insights and state-of-the-art facilities
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Methoxy Polyethylene Glycol (m-PEGs)
Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...
Read More
Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones
2020
A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...
Read More-
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation
2005
An improved and rapid synthesis of mefenamic acid based indole derivatives has been achieved via the ligand free Cu-catalyzed coupling-cyclization method under ultrasound irradiation. This simple, straightforward and inexpensive one-pot method involved the reaction of a terminal alkyne derived from mefenamic acid with 2- iodosulfanilides in the presence of CuI ...
Read More -
Formal synthesis of Cladospolide C & epi-Cladospolide C using R- (þ)-g-valerolactone as a chiral synthon
2005
The formal synthesis of Cladospolide-C and its analog is achieved by using enantiopure (R)-g evalerolactone 10. The significant points of this synthesis are the stereoselective dihydroxylation of a, bunsaturated ester 16 using Sharpless protocol, Wittig olefination of g evalerolactol 6 with triphenylphosphonium iodide salt 7, one pot selective oxidation ...
Read More -
Amberlite-15 promoted an unprecedented aza Michael rearrangement for one pot synthesis of dihydroquinazolinone compounds
2005
A new one pot multicomponent annulation strategy for the synthesis of various dihydroquinazolinone compounds has been developed using Amberlite-15 as a catalyst, giving good to moderate yields. In this reaction the substrate scope for amines and aldehydes was also investigated. The reaction has been checked on a large scale ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market